Jump to Navigation

Abilify Injuries

Synopsis of Prescription Drug Litigation

Abilify is an atypical antipsychotic and antidepressant used in the treatment of schizophrenia, bipolar disorder and clinical depression. It was approved by the US FDA for schizophrenia on November 15, 2002; for acute manic and mixed episodes associated with bipolar disorder on October 1, 2004; as an adjunct (additional) for major depressive disorder (MDD) on November 20, 2007; and to treat irritability in children with autism on November 20, 2009.

Aripripazole is associated with a number of serious and life-threatening adverse reactions that include: dangerous blood clots such as deep vein thrombosis (DVT) and pulmonary embolism, diabetes, Neuroleptic Malignant Syndrome (NMS) and Tardive Dyskinesia (TD). NMS is a potentially fatal syndrome involving muscle rigidity, an altered mental status and symptoms of cardiac instability (irregular blood pressure, heart rate and pulse). The FDA has become concerned about the possibility of a specific and potentially fatal heart rhythm irregularity called torsade de pointes. Tardive Dyskinesia (TD) is a central nervous system disorder characterized by involuntary movements of the limbs as well as twitching of the face and tongue. It can be a permanent and debilitating disease. Abilify can also cause cause the body to lose regulation of core body temperature known as malignant hyperthermia.

Abilify® (aripripazole): Manufactured by Bristol Myers, Squibb and developed and co-marketed with Otsuka America and approved by the FDA in November of 2002. Abilify is one of Bristol Myers, Squibb's strongest sellers. In 2009, it had a 22 percent increase over the previous year with sales of $2.8 billion annually. Since its approval, Abilify has gone through 11 labeling revisions and major black box warning additions.

Why is this medication prescribed?: Aripiprazole is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) in adults and teenagers 13 years of age and older. It is also used alone or with other medications to treat episodes of mania or mixed episodes (symptoms of mania and depression that happen together) in adults, teenagers, and children 10 years of age and older with bipolar disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Aripiprazole is also used with an antidepressant to treat depression when symptoms cannot be controlled by the antidepressant alone. Aripiprazole is also used to treat children 6 to 17 years of age who have autistic disorder (a developmental problem that causes difficulty communicating and interacting with others). Aripiprazole may help control irritable behavior such as aggression, temper tantrums, and frequent mood changes in these children. Aripiprazole is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.

What you should know before taking Abilify:

Before taking aripiprazole,

  • tell your doctor and pharmacist if you are allergic to aripiprazole, any other medications, or any of the ingredients in aripiprazole tablets, orally disintegrating tablets, or oral solution. Ask your doctor or pharmacist for a list of the ingredients..
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: antidepressants (mood elevators); antifungals such as itraconazole (Sporanox) and ketoconazole (Nizoral); antihistamines; bupropion (Wellbutrin); carbamazepine (Tegretol); clarithromycin (Biaxin); fluoxetine (Prozac, Sarafem); HIV protease inhibitors such as atazanavir (Reyataz), indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir), and saquinavir (Invirase); ipratropium (Atrovent); medications for anxiety, high blood pressure, irritable bowel syndrome, mental illness, motion sickness, Parkinson's disease, seizures, ulcers, or urinary problems; nefazodone; paroxetine (Paxil, Pexeva); quinidine;rifampin (Rifadin, Rimactane); sedatives; sleeping pills; telithromycin (Ketek); and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with aripiprazole, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor if you use or have ever used street drugs or have overused prescription medication and if you have or have ever had heart disease, heart failure, a heart attack, an irregular heartbeat, high or low blood pressure, a stroke, a ministroke, seizures, a low number of white blood cells,or any condition that makes it difficult for you to swallow. Tell your doctor if you or anyone in your family has or has ever had diabetes. Also tell your doctor if you have ever had to stop taking a medication for mental illness because of severe side effects.
  • tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breast-feeding. If you become pregnant while taking aripiprazole, call your doctor. Aripiprazole may cause problems in newborns following delivery if it is taken during the last months of pregnancy.
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking aripiprazole.
  • you should know that aripiprazole may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.
  • you should know that alcohol can add to the drowsiness caused by this medication. Do not drink alcohol while taking aripiprazole.
  • you should know that you may experience hyperglycemia (increases in your blood sugar) while you are taking this medication, even if you do not already have diabetes. If you have schizophrenia, you are more likely to develop diabetes than people who do not have schizophrenia, and taking aripiprazole or similar medications may increase this risk. Tell your doctor immediately if you have any of the following symptoms while you are taking aripiprazole: extreme thirst, frequent urination, extreme hunger, blurred vision, or weakness. It is very important to call your doctor as soon as you have any of these symptoms, because high blood sugar that is not treated can cause a serious condition called ketoacidosis. Ketoacidosis may become life-threatening if it is not treated at an early stage. Symptoms of ketoacidosis include: dry mouth, nausea and vomiting, shortness of breath, breath that smells fruity, and decreased consciousness.
  • you should know that aripiprazole may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. This is more common when you first start taking aripiprazole. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.
  • you should know that aripiprazole may make it harder for your body to cool down when it gets very hot. Tell your doctor if you plan to do vigorous exercise or be exposed to extreme heat.
  • if you have phenylketonuria (PKU, an inherited condition in which a special diet must be followed to prevent mental retardation), you should know that the orally disintegrating tablets contain phenylalanine. If you have diabetes, you should know that aripiprazole solution contains sugar.
  • you should know that when aripiprazole is used to treat children, it should be used as part of a treatment program that may include counseling and special education. Be sure that your child follows all of his or her doctor's or therapist's instructions.

Black Box Warning:

WARNING:

Increased Mortality in Elderly Patients with Dementia Related Psychosis

  • Elderly patients with dementia related psychosis treated with atypical antipsychotic drugs are at increased risk of death compared to placebo
  • Analysis of seventeen placebo controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug treated patients of between 1.6 to 1.7 times that seen in placebo treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug treated patients was about 4.5% compared to a rate of about 2.6% in the placebo group.
  • Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.
  • Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality.
  • The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristc(s) of the patients is not clear.
  • This drug is not approved for the treatment of patients with dementia-related psychosis (See WARNINGS in patient package insert for drug).

Suicidality and Antidepressant Drugs

  • Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders.
  • Anyone considering the use of adjunctive Abilify or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.
  • Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adultsl beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.
  • Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide.
  • Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality or unusual changes in behavior.
  • Families and caregivers should be advised of the need for close observation and communication with the prescriber. Abilify is not approved for use in pediatric patients with depression.

Lawsuits: STATUS OF ABILIFY LITIGATION: There are currently hundreds of lawsuits involving Abilify throughout the U.S. With its documented high profile of serious adverse effects, aggressive marketing by the manufacturer and off label uses, litigation is furiously on the rise for Abilify.

When to call the Venardi Law Firm: The antipsychotic aripiprazole-sold under the brand name Abilify and less commonly as Aripiprex-might have caused you to suffer life-threatening side effects. The medication, prescribed to you by your doctor, was supposed to ease your depression, schizophrenia and bipolar disorder-not expose you to greater risk.

The manufacturer alone is at fault. Certainly, you're not to blame. And you shouldn't have to go through more trouble to be compensated for the harm you've already suffered. The Venardi Law Firm, an Abilify law group, knows this, and we want you to believe it. Because the drug manufacturer put its own profits before your well-being, now you need a sympathetic advocate who will represent only your interests-and who will make the process as painless as possible. If you have taken Abilify and been harmed, contact The Venardi Law Firm today for a free consultation.

Click Here For Your Free Case Evaluation
Free Case Evaluation

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close
Recent Posts
Contact UsPrint Page

The Venardi Law Firm
2033 North Main Street, Suite 750
Walnut Creek CA 94596

Telephone: 925-478-5557
Telephone: 888-732-7047
Fax: 925-937-3905

Walnut Creek Law Office
Email the Firm

785 Market Street, 16th Floor
San Francisco, CA 94103
Telephone: 415-255-5638
San Francisco Law Office

790 Mission Avenue
San Rafael, CA 94901
Telephone: 510-270-5772
San Rafael Law Office

AV | LexisNexis Martindale-Hubbell | Peer Review Rated For Ethical Standards and Legal Ability

Mark Venardi has earned an AV rating by Martindale Hubbell every year since 2004. This is the highest achievement given by the peer review rating system.

Super Lawyers 2010

Mark was named a California Super Lawyer in 2009 and 2010.

Million Dollar Advocates Forum San Francisco Trial Lawyers Association Consumer Attorneys of California The American Trial Lawyers Association